bioMerieux (OTCMKTS:BMXMF) Stock Crosses Below Fifty Day Moving Average – What’s Next?

bioMerieux (OTCMKTS:BMXMF) shares crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $92.82 and traded as low as $84.0750. bioMerieux shares last traded at $84.0750, with a volume of 6 shares trading hands.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on BMXMF shares. Deutsche Bank Aktiengesellschaft downgraded bioMerieux from a “buy” rating to a “hold” rating in a research note on Friday, April 24th. Zacks Research upgraded bioMerieux to a “hold” rating in a research note on Tuesday, April 28th. Finally, UBS Group downgraded bioMerieux from a “buy” rating to a “neutral” rating in a research note on Monday. Four investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has an average rating of “Hold”.

bioMerieux Stock Down 0.2%

The business’s fifty day moving average price is $92.82 and its 200-day moving average price is $110.81. The company has a current ratio of 2.39, a quick ratio of 1.48 and a debt-to-equity ratio of 0.08.

bioMerieux Company Profile

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.